Management of AIDS-related Kaposi's sarcoma.

[1]  S. Krown.  AIDS-associated Kaposi's sarcoma: is there still a role for interferon alfa? , 2007, Cytokine & growth factor reviews.

[2]  S. Steinberg,et al.  Treatment of AIDS-related Kaposi's sarcoma with interleukin-12: rationale and preliminary evidence of clinical activity. , 2007, Critical reviews in immunology.

[3]  D. Henry,et al.  A randomized, double-blind study of pegylated liposomal doxorubicin for the treatment of AIDS-related Kaposi's sarcoma. , 2007, The oncologist.

[4]  R. Sullivan,et al.  Signal transduction targets in Kaposi's sarcoma , 2006, Current opinion in oncology.

[5]  J. Goedert,et al.  Trends in cancer risk among people with AIDS in the United States 1980–2002 , 2006, AIDS.

[6]  D. Costagliola,et al.  Differential impact of combination antiretroviral therapy in preventing Kaposi's sarcoma with and without visceral involvement. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[7]  D. Bottke,et al.  Radiotherapy in the Management of Kaposi’s Sarcoma , 2006, Oncology Research and Treatment.

[8]  M. Genc,et al.  Radiotherapy in the management of Kaposi's sarcoma: comparison of 8 Gy versus 6 Gy. , 2006, Journal of the National Medical Association.

[9]  B. Gazzard,et al.  A prognostic index for AIDS-associated Kaposi's sarcoma in the era of highly active antiretroviral therapy , 2006, The Lancet.

[10]  L. Pantanowitz,et al.  Kaposi sarcoma of the larynx. , 2006, The AIDS reader.

[11]  K. Bauer,et al.  Randomized phase II trial of matrix metalloproteinase inhibitor COL-3 in AIDS-related Kaposi's sarcoma: an AIDS Malignancy Consortium Study. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[12]  M. Lipman,et al.  Immune reconstitution inflammatory syndrome in HIV , 2006, Current opinion in infectious diseases.

[13]  Ulrich Beyer,et al.  Liposomal encapsulated anti-cancer drugs. , 2005, Anti-cancer drugs.

[14]  C. Thirlwell,et al.  Immune reconstitution inflammatory syndrome associated with Kaposi's sarcoma. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[15]  J. Kigula-Mugambe,et al.  Epidemic and endemic Kaposi's sarcoma: a comparison of outcomes and survival after radiotherapy. , 2005, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

[16]  L. Pantanowitz,et al.  AIDS-related malignancies: emerging challenges in the era of highly active antiretroviral therapy. , 2005, The oncologist.

[17]  M. Lichterfeld,et al.  Treatment of HIV-1-Associated Kaposi’s Sarcoma with Pegylated Liposomal Doxorubicin and HAART Simultaneously Induces Effective Tumor Remission and CD4+ T Cell Recovery , 2005, Infection.

[18]  C. Leport,et al.  Docetaxel in anthracycline‐pretreated AIDS‐related Kaposi's sarcoma: a retrospective study , 2005, The British journal of dermatology.

[19]  L. Gesualdo,et al.  Sirolimus for Kaposi's sarcoma in renal-transplant recipients. , 2005, The New England journal of medicine.

[20]  L. Pantanowitz,et al.  Unusual Sites of Malignancies: CASE 3. AIDS-related Kaposi's sarcoma of the gastrointestinal tract. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[21]  L. Pantanowitz,et al.  Imatinib-induced regression of AIDS-related Kaposi's sarcoma. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[22]  A. Levine,et al.  Weekly docetaxel is safe and effective in the treatment of advanced‐stage acquired immunodeficiency syndrome‐related Kaposi sarcoma , 2005, Cancer.

[23]  T. Gambichler,et al.  Liposomal Pegylated Doxorubicin versus Low-Dose Recombinant Interferon Alfa-2a in the Treatment of Advanced Classic Kaposi's Sarcoma; Retrospective Analysis of Three German Centers , 2005, Cancer investigation.

[24]  S. Remick,et al.  Kaposi's sarcoma in patients with and without human immunodeficiency virus infection, in a tertiary referral centre in Kenya , 2005, Annals of tropical medicine and parasitology.

[25]  M. Kane,et al.  Immune reconstitution inflammatory syndrome associated with Kaposi sarcoma during potent antiretroviral therapy. , 2004, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[26]  Theresa M Allen,et al.  Advantages of liposomal delivery systems for anthracyclines. , 2004, Seminars in oncology.

[27]  L. Pantanowitz,et al.  Management of AIDS-related Kaposi sarcoma: advances in target discovery and treatment. , 2004, The AIDS reader.

[28]  C. Cockerell,et al.  Histological Features of Kaposi Sarcoma in a Patient Receiving Highly Active Antiviral Therapy , 2004, The American Journal of dermatopathology.

[29]  S. Krown.  Highly active antiretroviral therapy in AIDS-associated Kaposi's sarcoma: implications for the design of therapeutic trials in patients with advanced, symptomatic Kaposi's sarcoma. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[30]  L. Xerri,et al.  A multicentre study of percentage change in venous leg ulcer area as a prognostic index of healing at 24 weeks , 2003, The British journal of dermatology.

[31]  A. d’Arminio Monforte,et al.  AIDS-related Kaposi's Sarcoma: evaluation of potential new prognostic factors and assessment of the AIDS Clinical Trial Group Staging System in the Haart Era--the Italian Cooperative Group on AIDS and Tumors and the Italian Cohort of Patients Naive From Antiretrovirals. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[32]  B. Gazzard,et al.  A comparison of regimens based on non-nucleoside reverse transcriptase inhibitors or protease inhibitors in preventing Kaposi's sarcoma , 2003, AIDS.

[33]  R. Schwartz,et al.  Molecular Genetics of Kaposi's Sarcoma-Associated Herpesvirus (Human Herpesvirus 8) Epidemiology and Pathogenesis , 2003, Microbiology and Molecular Biology Reviews.

[34]  B. Gazzard,et al.  How does HAART lead to the resolution of Kaposi's sarcoma? , 2003, The Journal of antimicrobial chemotherapy.

[35]  B. Gazzard,et al.  Kaposi's sarcoma — an update , 2003, International journal of STD & AIDS.

[36]  S. Rafii,et al.  Kaposi's sarcoma associated herpesvirus G protein-coupled receptor immortalizes human endothelial cells by activation of the VEGF receptor-2/ KDR. , 2003, Cancer cell.

[37]  B. Druker,et al.  Kaposi's Sarcoma-Associated Herpesvirus-Induced Upregulation of the c-kit Proto-Oncogene, as Identified by Gene Expression Profiling, Is Essential for the Transformation of Endothelial Cells , 2002, Journal of Virology.

[38]  A. Mohar,et al.  Intralesional vinblastine vs. 3% sodium tetradecyl sulfate for the treatment of oral Kaposi's sarcoma. A double blind, randomized clinical trial. , 2002, Oral oncology.

[39]  A. Tulpule,et al.  Multicenter trial of low‐dose paclitaxel in patients with advanced AIDS‐related Kaposi sarcoma , 2002, Cancer.

[40]  M. Reitz,et al.  Antitumorigenic effects of HIV protease inhibitor ritonavir: inhibition of Kaposi sarcoma. , 2002, Blood.

[41]  J. V. Von Roenn,et al.  Efficacy of low-dose interferon with antiretroviral therapy in Kaposi's sarcoma: a randomized phase II AIDS clinical trials group study. , 2002, Journal of interferon & cytokine research : the official journal of the International Society for Interferon and Cytokine Research.

[42]  U. Tirelli,et al.  AIDS-related tumors: integrating antiviral and anticancer therapy. , 2002, Critical reviews in oncology/hematology.

[43]  M. Falchi,et al.  HIV protease inhibitors are potent anti-angiogenic molecules and promote regression of Kaposi sarcoma , 2002, Nature Medicine.

[44]  E. Cesarman,et al.  Human herpesvirus-8-transformed endothelial cells have functionally activated vascular endothelial growth factor/vascular endothelial growth factor receptor. , 2002, The American journal of pathology.

[45]  M. Hidalgo,et al.  Development of matrix metalloproteinase inhibitors in cancer therapy. , 2001, Journal of the National Cancer Institute.

[46]  D. Osoba,et al.  Effect of Treatment on Health-Related Quality of Life in Acquired Immunodeficiency Syndrome (AIDS)-Related Kaposi's Sarcoma: A Randomized Trial of Pegylated-Liposomal Doxorubicin Versus Doxorubicin, Bleomycin, and Vincristine , 2001, Cancer investigation.

[47]  L. Chieco‐Bianchi,et al.  Acquired immunodeficiency syndrome-related Kaposi's sarcoma regression after highly active antiretroviral therapy: biologic correlates of clinical outcome. , 2000, Journal of the National Cancer Institute. Monographs.

[48]  S. Steinberg,et al.  Activity of thalidomide in AIDS-related Kaposi's sarcoma. , 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[49]  Y. Chang,et al.  Kaposi's sarcoma. , 2000, The New England journal of medicine.

[50]  A. Folpe,et al.  Vascular Endothelial Growth Factor Receptor-3 (VEGFR-3): A Marker of Vascular Tumors with Presumed Lymphatic Differentiation, Including Kaposi's Sarcoma, Kaposiform and Dabska-Type Hemangioendotheliomas, and a Subset of Angiosarcomas , 2000, Modern Pathology.

[51]  M. Skobe,et al.  Vascular endothelial growth factor-C (VEGF-C) and its receptors KDR and flt-4 are expressed in AIDS-associated Kaposi's sarcoma. , 1999, The Journal of investigative dermatology.

[52]  L. Chieco‐Bianchi,et al.  Regression of AIDS-related Kaposi's sarcoma following antiretroviral therapy with protease inhibitors: biological correlates of clinical outcome. , 1999, European journal of cancer.

[53]  S. Walmsley,et al.  Treatment of AIDS-related cutaneous Kaposi's sarcoma with topical alitretinoin (9-cis-retinoic acid) gel. Panretin Gel North American Study Group. , 1999, Journal of acquired immune deficiency syndromes.

[54]  B. Gazzard,et al.  Highly active anti-retroviral therapy (HAART) prolongs time to treatment failure in Kaposi's sarcoma. , 1999, AIDS.

[55]  T. Mang,et al.  Photofrin photodynamic therapy for treatment of AIDS-related cutaneous Kaposi's sarcoma. , 1999, AIDS.

[56]  A. Telenti,et al.  Risk of HIV related Kaposi's sarcoma and non-Hodgkin's lymphoma with potent antiretroviral therapy: prospective cohort study , 1999, BMJ.

[57]  E. Jaffe,et al.  Angiogenesis and hematopoiesis induced by Kaposi's sarcoma-associated herpesvirus-encoded interleukin-6. , 1999, Blood.

[58]  E. Mesri.  Inflammatory reactivation and angiogenicity of Kaposi's sarcoma-associated herpesvirus/HHV8: a missing link in the pathogenesis of acquired immunodeficiency syndrome-associated Kaposi's sarcoma. , 1999, Blood.

[59]  B. Corn,et al.  Palliative treatment of epidemic Kaposi sarcoma of the feet. , 1999, American journal of clinical oncology.

[60]  E. van Marck,et al.  Distribution of human herpesvirus-8 latently infected cells in Kaposi's sarcoma, multicentric Castleman's disease, and primary effusion lymphoma. , 1999, Proceedings of the National Academy of Sciences of the United States of America.

[61]  S. Tyring,et al.  Serologic and molecular evidence of human herpesvirus 8 activation in renal transplant recipients. , 1998, The Journal of infectious diseases.

[62]  T. Marique,et al.  Constitutive release of metalloproteinase-9 (92-kd type IV collagenase) by Kaposi's sarcoma cells. , 1998, Journal of acquired immune deficiency syndromes and human retrovirology : official publication of the International Retrovirology Association.

[63]  M A Fischl,et al.  Pegylated-liposomal doxorubicin versus doxorubicin, bleomycin, and vincristine in the treatment of AIDS-related Kaposi's sarcoma: results of a randomized phase III clinical trial. , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[64]  J. Singer,et al.  Prospective randomized trial of two dose levels of interferon alfa with zidovudine for the treatment of Kaposi's sarcoma associated with human immunodeficiency virus infection: a Canadian HIV Clinical Trials Network study. , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[65]  J. V. Von Roenn,et al.  Fumagillin analog in the treatment of Kaposi's sarcoma: a phase I AIDS Clinical Trial Group study. AIDS Clinical Trial Group No. 215 Team. , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[66]  W. Wilson,et al.  Phase II trial with dose titration of paclitaxel for the therapy of human immunodeficiency virus-associated Kaposi's sarcoma. , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[67]  S. Stewart,et al.  Randomized comparative trial of pegylated liposomal doxorubicin versus bleomycin and vincristine in the treatment of AIDS-related Kaposi's sarcoma. International Pegylated Liposomal Doxorubicin Study Group. , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[68]  P. Piedbois,et al.  Radiotherapy in the management of epidemic Kaposi's sarcoma: a retrospective study of 643 cases. , 1998, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

[69]  M. Testa,et al.  AIDS-related Kaposi's sarcoma: prospective validation of the AIDS Clinical Trials Group staging classification. AIDS Clinical Trials Group Oncology Committee. , 1997, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[70]  D. Ganem,et al.  Sensitivity of Kaposi's sarcoma-associated herpesvirus replication to antiviral drugs. Implications for potential therapy. , 1997, The Journal of clinical investigation.

[71]  G. Hayward,et al.  Kaposi's sarcoma-associated human herpesvirus-8 encodes homologues of macrophage inflammatory protein-1 and interleukin-6 , 1997, Nature Medicine.

[72]  G. Viale,et al.  The microtubule-affecting drug paclitaxel has antiangiogenic activity. , 1996, Clinical cancer research : an official journal of the American Association for Cancer Research.

[73]  P. Swift.  The role of radiation therapy in the management of HIV-related Kaposi's sarcoma. , 1996, Hematology/oncology clinics of North America.

[74]  J. V. Von Roenn,et al.  Randomized phase III trial of liposomal daunorubicin versus doxorubicin, bleomycin, and vincristine in AIDS-related Kaposi's sarcoma. , 1996, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[75]  J. Phair,et al.  Use of antiherpes drugs and the risk of Kaposi's sarcoma: data from the Multicenter AIDS Cohort Study. , 1996, The Journal of infectious diseases.

[76]  I. Hewlett,et al.  HIV-1-Tat modulates the function of monocytes and alters their interactions with microvessel endothelial cells. A mechanism of HIV pathogenesis. , 1996, Journal of immunology.

[77]  P. Reiss,et al.  Photodynamic therapy in AIDS-related cutaneous Kaposi's sarcoma. , 1995, Journal of acquired immune deficiency syndromes and human retrovirology : official publication of the International Retrovirology Association.

[78]  W. Webb,et al.  AIDS-related Kaposi sarcoma of the lung: radiographic findings and staging system with bronchoscopic correlation. , 1995, Radiology.

[79]  J. Melamed,et al.  Kaposi's sarcoma of internal organs. A multiparameter study of 86 cases , 1995, Cancer.

[80]  P. Lacal,et al.  Regulation of PDGF-B and PDGF receptor expression in the pathogenesis of Kaposi's sarcoma in AIDS. , 1994, Antibiotics and chemotherapy.

[81]  C. Flaitz,et al.  Treating Kaposi's lesions in the HIV-infected patient. , 1993, Journal of the American Dental Association.

[82]  P. Hofschneider,et al.  Expression of platelet-derived growth factor and its receptor in AIDS-related Kaposi sarcoma in vivo suggests paracrine and autocrine mechanisms of tumor maintenance. , 1992, Proceedings of the National Academy of Sciences of the United States of America.

[83]  R. Macklis.  Atypical Radiation Toxicity in Patients with Classical Kaposi's Sarcoma , 1991, Tumori.

[84]  J. Kahn,et al.  Cryotherapy for Cutaneous Kaposi's Sarcoma (KS) Associated with Acquired Immune Deficiency Syndrome (AIDS): A Phase II Trial , 1991, Journal of acquired immune deficiency syndromes.

[85]  S. Krown,et al.  Kaposi's sarcoma in the acquired immune deficiency syndrome: a proposal for uniform evaluation, response, and staging criteria. AIDS Clinical Trials Group Oncology Committee. , 1989, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[86]  S. Krown,et al.  Kaposi's Sarcoma in the Acquired Immune Deficiency Syndrome: A Proposal for Uniform Evaluation, Response, and Staging Criteria , 1989 .